Dren Bio Raises $350 Million for Biotech Pipeline

The San Carlos-based firm will fund late-stage development of its lead therapeutic antibody, dibotatug.

Updated on Oct. 29, 2026 in Biotech

Isometric editorial illustration showing clean glass laboratory vials and a pipette on a sterile surface, representing biotech research. — Dren Bio has secured $350 million in private financing to accelerate the late-stage development and commercial launch of its lead therapeutic antibody, dibotatug. AI Illustration. Upload story photo >

Live Poll

Does large-scale private investment in biotech companies effectively improve the development of new medical treatments?

Dren Bio has successfully closed an oversubscribed $350 million private financing round to advance its proprietary antibody therapeutics. The capital will support regulatory submissions and the upcoming commercial launch of its lead candidate, dibotatug.

Why it matters

The funding provides Dren Bio with the resources to expand dibotatug into additional medical indications while accelerating the growth of its broader pipeline. This infusion of capital positions the company to transition its lead asset from late-stage clinical trials to the commercial market.

Dren Bio utilizes a proprietary Targeted Myeloid Engager and Phagocytosis Platform to develop its therapies. Its lead candidate, dibotatug, is a monoclonal antibody targeting CD94 that has already been administered to more than 300 patients in clinical trials.

The players

Dren Bio

A San Carlos-based biotechnology company focused on developing antibody therapeutics using its proprietary myeloid engager platform.

Sujal Shah

A new addition to the Dren Bio Board of Directors who brings extensive experience in the biotechnology leadership sector.

Shelley Chu

A newly appointed member of the Dren Bio Board of Directors who contributes significant expertise to the company's strategic growth.

The details

Co-led by Juvia Group and Lightspeed Venture Partners, the round included participation from a wide array of new and existing institutional investors. The company, which received the 2025 Prix Galien USA Award for Best Biotech Startup, is scaling operations to support its transition toward commercial-stage activities.

Dren Bio was founded in 2019.
Sanofi acquired the platform lead program DR-0201 in May 2025.
The $350 million financing was announced on October 29, 2026.

The Tech Race

This financing round solidifies Dren Bio's standing within the competitive landscape of targeted antibody development. It reflects a broader trend of significant private capital flowing into firms that have successfully moved complex therapeutic platforms through human clinical trials.

For patients suffering from cytotoxic T-cell lymphoma and large granular lymphocytic leukemia, this funding ensures the continued development of a potential new treatment option. The progress of the dibotatug clinical program remains a key metric to watch for those tracking advancements in specialized oncology care.

The takeaway

Large private financing rounds are increasingly critical for biotech firms looking to bridge the gap between late-stage research and market entry. Investors are currently showing a strong preference for companies with validated clinical trial data and proprietary technology platforms.